Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hypoxia-inducible factor 2 alpha (HIF-2 alpha) promoter G-quadruplex is a non-canonical, four-stranded nucleic acid structure located within the guanine-rich regulatory region of the EPAS1 gene. This structural motif acts as a molecular switch that modulates the transcription of HIF-2 alpha, a transcription factor essential for the cellular response to low-oxygen environments. In normal physiology, HIF-2 alpha regulates genes involved in angiogenesis, red blood cell production, and metabolic adaptation; however, in many cancers, such as clear cell renal cell carcinoma, it is constitutively overexpressed and drives tumor progression. Small-molecule ligands, such as the experimental compound CL67, are designed to bind and stabilize this G-quadruplex structure, creating a physical barrier that prevents the transcriptional machinery from accessing the gene. This stabilization leads to the downregulation of EPAS1 mRNA and a subsequent decrease in HIF-2 alpha protein levels, offering a potential strategy to inhibit tumor growth and vascularization. Therapeutic challenges for this target include achieving high selectivity for the EPAS1 G-quadruplex over other genomic structures and managing potential systemic toxicity from the broad inhibition of hypoxia-responsive pathways.
Ligand-mediated stabilization of the G-quadruplex structure within the EPAS1 promoter, which sterically inhibits the binding of transcription factors or the progression of RNA polymerase, thereby reducing the transcription and expression of the HIF-2 alpha protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxia-inducible factor 2 alpha promoter G-quadruplex (HIF-2a G4).